作者: Jonathon Leipsic , Cameron J. Hague , Ronen Gurvitch , Amr M. Ajlan , Troy M. Labounty
DOI: 10.1016/J.CCL.2011.10.003
关键词: Transcatheter aortic 、 Mitral valve 、 Mitral valve repair 、 Percutaneous 、 Valve replacement 、 Aortic valve replacement 、 Surgery 、 Medicine 、 valvular heart disease 、 Stenosis 、 Cardiology and Cardiovascular Medicine 、 General Medicine
摘要: Percutaneous management of valvular heart disease is becoming a reality, with multicenter trials supporting minimally invasive procedures for both aortic and mitral valve disease. Historically, the treatment choice has been replacement conventional surgery patients severe stenosis, as prognosis untreated poor, particularly if patient symptomatic. Transcatheter now available option to treat select high-risk stenosis. At present more than 30,000 have performed worldwide, mostly confined at high surgical risk. The short- medium-term outcomes promising.